Calamos Wealth Management’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.67M Sell
20,811
-1
-0% -$117 0.08% 133
2026
Q1
$2.5M Buy
20,812
+1,522
+8% +$176K 0.09% 124
2025
Q4
$2.03M Buy
19,290
+3,529
+22% +$331K 0.07% 128
2025
Q3
$1.32M Buy
15,761
+1,351
+9% +$111K 0.05% 162
2025
Q2
$1.14M Sell
14,410
-3,630
-20% -$289K 0.05% 160
2025
Q1
$1.62M Sell
18,040
-1,984
-10% -$185K 0.08% 114
2024
Q4
$1.99M Sell
20,024
-119,488
-86% -$12.3M 0.1% 100
2024
Q3
$15.8M Buy
139,512
+17,991
+15% +$2.14M 0.81% 24
2024
Q2
$15M Sell
121,521
-15,493
-11% -$2M 0.8% 25
2024
Q1
$18.1M Buy
137,014
+2,922
+2% +$360K 1.01% 20
2023
Q4
$14.6M Sell
134,092
-1,139
-0.8% -$118K 0.92% 23
2023
Q3
$13.9M Buy
135,231
+115,843
+597% +$12.5M 1.06% 19
2023
Q2
$2.24M Buy
19,388
+286
+1% +$32.5K 0.16% 94
2023
Q1
$2.03M Sell
19,102
-605
-3% -$65.3K 0.16% 99
2022
Q4
$2.19M Sell
19,707
-119
-0.6% -$12.2K 0.17% 96
2022
Q3
$1.71M Buy
19,826
+7,306
+58% +$652K 0.15% 103
2022
Q2
$1.14M Buy
12,520
+86
+0.7% +$7.62K 0.1% 133
2022
Q1
$1.02M Sell
12,434
-3,969
-24% -$313K 0.08% 154
2021
Q4
$1.26M Buy
16,403
+307
+2% +$24.5K 0.09% 143
2021
Q3
$1.21M Sell
16,096
-439
-3% -$33.4K 0.1% 137
2021
Q2
$1.29M Sell
16,535
-740
-4% -$55K 0.1% 140
2021
Q1
$1.27M Sell
17,275
-1,364
-7% -$101K 0.1% 139
2020
Q4
$1.46M Buy
18,639
+2,124
+13% +$162K 0.13% 110
2020
Q3
$1.31M Sell
16,515
-42,983
-72% -$3.37M 0.15% 94
2020
Q2
$4.39M Sell
59,498
-4,482
-7% -$337K 0.55% 48
2020
Q1
$4.7M Buy
63,980
+2,039
+3% +$160K 0.72% 40
2019
Q4
$5.38M Buy
61,941
+975
+2% +$80.1K 0.63% 48
2019
Q3
$4.9M Buy
60,966
+1,280
+2% +$103K 0.65% 43
2019
Q2
$4.78M Sell
59,686
-652
-1% -$49.9K 0.64% 43
2019
Q1
$4.79M Buy
60,338
+41,921
+228% +$3.14M 0.68% 41
2018
Q4
$1.34M Buy
18,417
+5,956
+48% +$420K 0.2% 91
2018
Q3
$843K Sell
12,461
-353
-3% -$22.5K 0.11% 124
2018
Q2
$742K Sell
12,814
-277
-2% -$15.6K 0.09% 125
2018
Q1
$681K Sell
13,091
-88,519
-87% -$4.78M 0.09% 136
2017
Q4
$5.46M Sell
101,610
-12,245
-11% -$679K 0.71% 49
2017
Q3
$6.96M Buy
113,855
+797
+0.7% +$48.3K 0.96% 27
2017
Q2
$6.91M Buy
113,058
+1,555
+1% +$94.7K 0.98% 25
2017
Q1
$6.76M Buy
111,503
+2,498
+2% +$152K 1.01% 23
2016
Q4
$6.12M Buy
109,005
+317
+0.3% +$18.6K 0.99% 24
2016
Q3
$6.47M Buy
108,688
+3,809
+4% +$223K 1.11% 18
2016
Q2
$5.76M Buy
104,879
+5,151
+5% +$274K 1.02% 23
2016
Q1
$5.04M Buy
99,728
+8,559
+9% +$419K 0.97% 24
2015
Q4
$4.59M Buy
91,169
+1,961
+2% +$98.9K 0.92% 27
2015
Q3
$4.2M Buy
89,208
+2,587
+3% +$137K 1.01% 23
2015
Q2
$4.71M Buy
86,621
+22,788
+36% +$1.28M 1.11% 20
2015
Q1
$3.5M Buy
63,833
+5,480
+9% +$310K 0.87% 27
2014
Q4
$3.16M Sell
58,353
-544
-0.9% -$30.3K 0.91% 26
2014
Q3
$3.33M Buy
58,897
+1,499
+3% +$84.2K 0.96% 22
2014
Q2
$3.17M Sell
57,398
-2,080
-3% -$113K 0.9% 25
2014
Q1
$3.22M Buy
59,478
+181
+0.3% +$9.37K 0.95% 25
2013
Q4
$2.83M Buy
59,297
+1,820
+3% +$83.2K 0.87% 31
2013
Q3
$2.61M Buy
57,477
+3,491
+6% +$159K 0.85% 35
2013
Q2
$2.39M Buy
+53,986
New +$2.41M 0.85% 35

Other funds holding MRK

Calamos Wealth Management's MRK Position: Q2 2026 in Review

Calamos Wealth Management reduced its Merck (MRK) stake by 0% in Q2 2026, selling an estimated $117 and leaving 20,811 shares worth $2.67M. The position accounts for 0.08% of the portfolio, ranked #133.

Calamos Wealth Management first reported a position in MRK in Q2 2013 and has held it in 53 quarters since. The position peaked at $18.1M in Q1 2024. 1,867 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Calamos Wealth Management held 20,811 shares of Merck worth $2.67M as of Q2 2026.
  • Calamos Wealth Management sold 1 Merck share in Q2 2026, an estimated $117.
  • Merck made up 0.08% of Calamos Wealth Management's portfolio in Q2 2026, its #133 holding.
  • Calamos Wealth Management first reported a position in Merck in Q2 2013 and has held it in 53 quarters since.
  • Calamos Wealth Management's Merck position peaked at $18.1M in Q1 2024.
  • 1,867 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Calamos Wealth Management's 13F filing for Q2 2026, filed 31 Jul 2026.